Evidence map›Paper›PMID 28475899›Full record

ArticleCell2017

An Immune Atlas of Clear Cell Renal Cell Carcinoma.

Stéphane Chevrier, Jacob Harrison Levine, Vito Riccardo Tomaso Zanotelli, Karina Silina, Daniel Schulz, Marina Bacac, Carola Hermine Ries, Laurie Ailles, Michael Alexander Spencer Jewett, Holger Moch and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 645 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
645citing papers in PubMed, 4 pooled it
43.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

645 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,025 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. EREG-secreting THBS1Hepatobiliary surgery and nutrition · 2026
    Article
  17. Review
  18. Review
  19. Article
  20. Article

585 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 5 countries.

Stéphane ChevrierInstitute of Molecular Life Sciences, University of Zürich, Winterthurerstrasse 190, 8057 Zürich, Switzerland.
Jacob Harrison LevineComputational and Systems Biology Program, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10065, USA.
Vito Riccardo Tomaso ZanotelliInstitute of Molecular Life Sciences, University of Zürich, Winterthurerstrasse 190, 8057 Zürich, Switzerland; Systems Biology PhD Program, Life Science Zürich Graduate School, ETH Zürich and University of Zürich, 8057 Zürich, Switzerland.
Karina SilinaInstitute of Experimental Immunology, University of Zürich, Winterthurerstrasse 190, 8057 Zürich, Switzerland.
Daniel SchulzInstitute of Molecular Life Sciences, University of Zürich, Winterthurerstrasse 190, 8057 Zürich, Switzerland.
Marina BacacRoche Pharma Research and Early Development, Roche Innovation Center Zürich, Wagistrasse 18, 8952 Schlieren, Switzerland.
Carola Hermine RiesRoche Pharma Research and Early Development, Roche Innovation Center Munich, Nonnenwald 2, 82377 Penzberg, Germany.
Laurie AillesDepartment of Medical Biophysics, University of Toronto, Toronto ON M5G 1L7, Canada; Princess Margaret Cancer Center, University Health Network, Toronto ON M5G 1L7, Canada.
Michael Alexander Spencer JewettPrincess Margaret Cancer Center, University Health Network, Toronto ON M5G 1L7, Canada.
Holger MochInstitute for Surgical Pathology, University Hospital Zürich, Schmelzbergstrasse 12, 8091 Zürich, Switzerland.
Maries van den BroekInstitute of Experimental Immunology, University of Zürich, Winterthurerstrasse 190, 8057 Zürich, Switzerland.
Christian BeiselDepartment of Biosystems Science and Engineering, ETH Zürich, Mattenstrasse 26, 4058 Basel, Switzerland.
Michael Beda StadlerFriedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, 4058 Basel, Switzerland; Swiss Institute of Bioinformatics, Mattenstrasse 26, 4058 Basel, Switzerland.
Craig GedyeSchool of Biomedical Sciences and Pharmacy, Hunter Medical Research Institute, University of Newcastle, Newcastle, NSW 2035, Australia.
Bernhard ReisRoche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070 Basel, Switzerland.
Dana Pe'erComputational and Systems Biology Program, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10065, USA.
Bernd BodenmillerInstitute of Molecular Life Sciences, University of Zürich, Winterthurerstrasse 190, 8057 Zürich, Switzerland. Electronic address: bernd.bodenmiller@imls.uzh.ch.
University of Zurich · CHKettering University · USRoche (Switzerland) · CHUniversity Health Network · CAETH Zurich · CHFriedrich Miescher Institute · CHHunter Medical Research Institute · AURoche Pharma AG (Germany) · DEUniversity Hospital of Zurich · CH

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
CELLULAR AND MOLECULAR FOUNDATIONS OF BIOMEDICAL SCIENCET32GM008798 · NIGMS · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI PRYWES, RON M · 2001 to 2018
$6.3M
Single cell mapping of developmental trajectories underlying health and diseaseDP1HD084071 · NICHD · SLOAN-KETTERING INST CAN RESEARCH · PI PE'ER, DANA · 2014 to 2018
$4.2M
Integrative Cancer Genomics: Drivers, Pathways and DrugsR01CA164729 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI PE'ER, DANA · 2012 to 2016
$1.9M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA164729NICHD NIH HHS DP1 HD084071NIGMS NIH HHS T32 GM008798
6 · The paper itself

Abstract

Immune cells in the tumor microenvironment modulate cancer progression and are attractive therapeutic targets. Macrophages and T cells are key components of the microenvironment, yet their phenotypes and relationships in this ecosystem and to clinical outcomes are ill defined. We used mass cytometry with extensive antibody panels to perform in-depth immune profiling of samples from 73 clear cell renal cell carcinoma (ccRCC) patients and five healthy controls. In 3.5 million measured cells, we identified 17 tumor-associated macrophage phenotypes, 22 T cell phenotypes, and a distinct immune composition correlated with progression-free survival, thereby presenting an in-depth human atlas of the immune tumor microenvironment in this disease. This study revealed potential biomarkers and targets for immunotherapy development and validated tools that can be used for immune profiling of other tumor types.

Indexed as

Tumor MicroenvironmentCarcinoma, Renal CellHumansImage CytometryImmune ToleranceKidneyKidney NeoplasmsMacrophagesSingle-Cell AnalysisT-Lymphocytesclear cell renal cell carcinomaimmune cell atlasimmunosuppressionmacrophagemass cytometrysingle-cell analysisT cell

Identifiers

PMID28475899
PMCPMC5422211
OpenAlexW2611919322

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.